The Full Wiki

More info on Chlorproguanil hydrochloride-dapsone-artesunate

Chlorproguanil hydrochloride-dapsone-artesunate: Wikis

Advertisements
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Chlorproguanil-dapsone-artesunate (abbreviated CDA) is a new antimalarial treatment that entered Phase III clinical trials in 2006.

It consists of chlorproguanil hydrochloride, dapsone, and artesunate. (It can also be interpreted as Lapdap+artesunate).

It is being compared against artemether-lumefantrine (Coartem) and against chlorproguanil-dapsone Lapdap. This drug is being developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine.[1]

References

  1. ^ Das P (2006). "Promising anti-malarial enters phase II studies.". Lancet Infect Dis 6 (9): 551. doi:10.1016/S1473-3099(06)70571-0.  

External links

Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message